GlassScriptPhysician profile
Sharon Freeman Clevenger
NPI 1174527899
$22,045.61
in general payments reported to CMS, 2019-2025
15 companies · $665 in 2025
The $665 reported for 2025 was more than what a typical Psychiatric/Mental Health (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $244).
See the full distribution for Psychiatric/Mental Health (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $84.93 · 2022: $3,209 · 2023: $16K · 2024: $2,205 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $2,283 · Travel and Lodging: $435 · Education: $83.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,950.00 |
| Food and Beverage | $2,283.43 |
| Travel and Lodging | $435.21 |
| Education | $83.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20,088.83 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $794.18 | 2022-2025 | Caplyta |
| Alkermes, INC. | $337.32 | 2022-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $164.39 | 2024-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $150.22 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $113.36 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $74.11 | 2022-2025 | Spravato |
| Lundbeck LLC | $71.20 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $64.24 | 2024 | Ingrezza |
| Axsome Therapeutics, INC. | $54.99 | 2023-2025 | Auvelity |
| Corium, LLC | $49.12 | 2022-2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $41.45 | 2023-2025 | Qelbree, Qelbree |
| Dexcom, INC. | $14.81 | 2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $14.23 | 2025 | Rexulti |
| Braeburn INC. | $13.16 | 2024 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Clevenger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.